跳至主要内容
临床试验/NCT01125579
NCT01125579已完成不适用

NEURAPAS Balance in Children With Nervous Restlessness, e.g. Agitated Depression

Pascoe Pharmazeutische Praeparate GmbH1 个研究点 分布在 1 个国家目标入组 115 人开始时间: 2008年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
115
试验地点
1
主要终点
Change in Parent Child Behaviour Checklist (CBCL/4-18)

研究概览

简要总结

Purpose: To document data on effectiveness of NEURAPAS® balance (NPB) in the treatment of nervous restlessness in children aged 6 to 12.

Each patient is treated with NPB. No placebo group is established. Course and severity of symptoms is documented by a questionnaire on 13 common symptoms of nervous restlessness and a Visual Analogue Scale (VAS). A standardized questionnaire (Parent Child Behaviour Checklist (CBCL/4-18)) is completed. Choice and doses of therapy are at the respective physician's discretion. The planned treatment and observation period is 2 - 4 weeks.

详细描述

Purpose: To document data on effectiveness of NEURAPAS® balance (NPB) in the treatment of nervous restlessness in children aged 6 to 12.

Patients and methods: A prospective, non-interventional, non-randomized, observational study conducted in German pediatric practices. Each patient is treated with NPB. No placebo group is established. As subjective criteria to document course and severity of symptoms, a questionnaire on 13 common symptoms of nervous restlessness and a Visual Analogue Scale (VAS) is used. As an objective criterion, a standardized questionnaire (Parent Child Behaviour Checklist (CBCL/4-18)) is completed. Choice and doses of therapy are at the respective physician's discretion. The planned treatment and observation period is 2 - 4 weeks.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
6 Years 至 11 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • patients <6 and >12 years of age

结局指标

主要结局

Change in Parent Child Behaviour Checklist (CBCL/4-18)

时间窗: after 2 + 4 weeks´ treatment

Parent Child Behaviour Checklist (CBCL/4-18), standardized questionnaire

次要结局

  • Change of the impact of the child´s complaints on daily family life (VAS)(after 2 + 4 weeks)
  • Tolerability of NEURAPAS balance(after 2 + 4 weeks)
  • Change of 13 common symptoms of nervous restlessness(after 2 + 4 weeks)

研究者

发起方
Pascoe Pharmazeutische Praeparate GmbH
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验